Treatment

• NanoViricides, Inc. (NYSE American: NNVC) announced on August 31, 2026, that it is preparing for clinical trials of its broad-spectrum drug candidate, NV-387. • The drug utilizes host-mimetic nanomedicine technology designed to treat measles, a disease currently seeing a rise in cases both within the USA and globally. • This development is significant as it aims to provide a revolutionary antiviral treatment that viruses cannot easily escape, addressing a critical gap in measles management.

• Moderna and Merck announced on August 19, 2026, that their personalized mRNA vaccine, intismeran autogene, successfully passed a late-stage clinical trial. • The vaccine was used in combination with the immunotherapy drug Keytruda to effectively reduce the recurrence of melanoma, a form of skin cancer. • This milestone represents a significant breakthrough in oncology, demonstrating the potential for mRNA technology to transform both cancer treatment and prevention.

• Mark Orwig participated in a clinical trial for an mRNA vaccine designed to prevent the recurrence of melanoma after surgical tumor removal. • The treatment targets lingering cancer cells that often remain in the body post-surgery, which typically lead to the disease returning. • Scientists believe this personalized mRNA approach could revolutionize cancer care by transforming how doctors treat high-risk patients.

• Moderna and Merck have reported positive results from a large Phase 3 clinical trial of a personalized mRNA-based cancer vaccine designed to treat melanoma. • Unlike traditional treatments, this therapy trains a patient's own immune system to recognize and destroy the specific cancer cells threatening them. • This breakthrough represents a major step forward in precision oncology, moving away from broad attacks on cancer cells toward highly targeted immunotherapy.

Chester zoo resident, 23, ‘back to her usual feisty self’ after electrochemotherapy for tumour in her jawA 15ft (4.5-metre) python is believed to be the first snake in the world to be given a pioneering, life-saving cancer treatment normally used on humans.The 50kg reticulated python, named Jodie Foster after the Hollywood star, has just turned 23 and lives at Chester zoo. Keepers first became concerned that she may be unwell when she began eating less and spending more time inactive in her habitat. Continue reading...

• Moderna and Merck announced that an experimental mRNA vaccine effectively prevented skin cancer recurrence in a large-scale clinical trial. • The therapy utilizes the same messenger RNA technology used in COVID-19 vaccines to deliver a customized treatment tailored to a patient's specific tumors. • This development represents a landmark moment in oncology, demonstrating the potential for personalized vaccines to treat and prevent the return of malignant tumors.

• The FDA has approved Pasatru™ (garetosmab-grts) as the first and only treatment to reduce new heterotopic ossification (HO) lesions and clinician-assessed flare-ups in adults with Fibrodysplasia Ossificans Progressiva (FOP). • The approval follows the OPTIMA Phase 3 clinical trial, a multinational study designed to evaluate the drug's efficacy, safety, tolerability, and pharmacokinetics in patients with active FOP. • This development is significant as it provides a targeted therapeutic option for a rare disease, supported by previous Fast Track and Orphan Drug designations from the FDA, EMA, and Japan's Ministry of Health.

• Moderna and Merck are developing personalized cancer vaccines designed to train the immune system to target mutations specific to an individual's tumor. • The treatment represents a potential breakthrough in oncology by shifting toward highly tailored immunotherapy rather than one-size-fits-all approaches. • Clinical trial results for colon cancer are anticipated in 2027, with data for pancreatic cancer trials expected to follow by 2031.

• Pakistani authorities have petitioned the Supreme Court to review or withdraw a mandate requiring imprisoned former Prime Minister Imran Khan to undergo a medical examination at a private hospital. • Information Minister Attaullah Tarar stated that while the government does not object to Khan receiving medical care, it challenges the specific requirement to use a private facility over prison-regulated treatment. • The government argues that health issues should remain separate from political disputes and maintains that Khan will continue to be treated according to established prison rules.

• NanoViricides, Inc. (NYSE American: NNVC) announced on August 18, 2026, that it will soon begin a Phase II clinical trial for NV-387 oral gummies. • The trial aims to treat the Bundibugyo Ebola virus during what is described as the largest and most rapidly expanding outbreak to date in the Democratic Republic of Congo. • This development is critical as the company seeks to provide an accessible, antiviral treatment that prevents viral escape during a major public health crisis.